{"relation": [["", "STARTED", "Treated", "COMPLETED", "NOT COMPLETED", "Death", "Adverse Event", "Lack of Efficacy", "Reason Unspecified", "Withdrawal by Subject"], ["Placebo: Core Study / Sildenafil: Extension Study", "115 [1]", "115", "53", "62", "24", "14", "5", "12", "7"], ["Sildenafil: Core Study / Sildenafil: Extension Study", "127 [1]", "127", "56", "71", "28", "14", "1", "19", "9"]], "pageTitle": "The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00159861?sect=Xc015&view=results", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 6, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043062723.96/warc/CC-MAIN-20150728002422-00200-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 874414361, "recordOffset": 874397967, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Period 1: \u00a0 Core Study - 16 Weeks Participant Flow for 2 periods Core Study (16 weeks, or at least 4 weeks for subjects who required a change in epoprostenol dose due to clinical deterioration): Sildenafil 20, 40, or 80 mg TID (3 times daily) based on toleration; Extension Study (until last enrolled subject completed 3 years of treatment): Sildenafil - initial dose 20 mg TID, may have been increased to 40 mg TID or 80 mg TID at discretion of Investigator Sildenafil: Core Study / Sildenafil: Extension Study Core Study: Placebo (16 weeks, or at least 4 weeks for subjects who required a change in epoprostenol dose due to clinical deterioration); Extension Study: Sildenafil (until last enrolled subject completed 3 years of treatment) - initial dose 20 mg TID (3 times daily), may have been increased to 40 mg TID or 80 mg TID at discretion of Investigator Placebo: Core Study / Sildenafil: Extension Study Description \u00a0 Reporting Groups Subjects were entered into the open-label extension study portion upon completion of the preceding 16-week, placebo controlled core study portion or, for subjects who required a change in epoprostenol dose due to clinical deterioration,", "textAfterTable": "Randomized but not Treated \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 [1] Entered A1481153: 115; Did not enter A1481153: 16 [2] Entered A1481153: 127; Did not enter A1481153: 7 Period 2: \u00a0 Extension Study - up to 3 Years \u00a0 \u00a0 Placebo: Core Study / Sildenafil: Extension Study \u00a0 \u00a0 Sildenafil: Core Study / Sildenafil: Extension Study \u00a0 STARTED \u00a0 \u00a0 115 [1] \u00a0 127 [1] Treated \u00a0 \u00a0 115 \u00a0 \u00a0 127 \u00a0 COMPLETED \u00a0 \u00a0 53 \u00a0 \u00a0 56 \u00a0 NOT COMPLETED", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}